Showing 4451-4460 of 6036 results for "".
- Researchers: Night Vision Tests in AMD Precisely Localize Disease Mechanismshttps://modernod.com/news/researchers-night-vision-tests-in-amd-precisely-localize-disease-mechanisms/2481479/Researchers at the University of Alabama at Birmingham discovered that night vision tests at a specific location in the retina will be suitable for assessing treatments and preventions for age-related macular degeneration (AMD), according to a university
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced
- Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Diseasehttps://modernod.com/news/kuria-therapeutics-completes-fda-pre-ind-consultation-for-topical-nrf2-activator-for-corneal-endothelial-disease/2481475/Kuria Therapeutics has announced it has completed a pre-investigational new drug (IND) interaction with the FDA and received positive feedback on its development program for KTX-1161 for corneal endothelial disease. KTX-1161 is a topical ophthalmic solution formulation of SCO-
- HCP Cureblindness Acquires SightLife Internationalhttps://modernod.com/news/hcp-cureblindness-acquires-sightlife-international/2481471/HCP Cureblindness announced it is acquiring SightLife International, the global division of the SightLife organization, with full integration of systems, programs, and brand to come over the next 12 months. Financial terms of the deal were not disclosed. F
- Researchers Discover Therapeutic Target to Aid in Glaucoma Treatmenthttps://modernod.com/news/researchers-discover-therapeutic-target-to-aid-in-glaucoma-treatment/2481470/Indiana University School of Medicine researchers have identified a new therapeutic target that could lead to more effective treatment of glaucoma, according to an article posted on the university website.
- LumiThera Announces Sustained Vision Improvement for 24 Months in Dry AMD Subjects from US LIGHTSITE III Trialhttps://modernod.com/news/lumithera-announces-sustained-vision-improvement-for-24-months-in-dry-amd-subjects-from-us-lightsite-iii-clinical-trial-data/2481469/LumiThera announced 24-month data from its LIGHTSITE III multicenter clinical trial which demonstrated sustained vision improvement in dry age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked
- GenSight Reports Topline Efficacy and Safety Results at 3 Years Post-Treatment with Lumevoqhttps://modernod.com/news/gensight-reports-topline-efficacy-and-safety-results-at-3-years-post-treatment-with-lumevoq/2481464/GenSight Biologics reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (lenadogene nolparvovec). The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene
- Visionix Unveils Second Generation VX 650 Multimodal Screener at Vision Expo 2023https://modernod.com/news/visionix-unveils-second-generation-vx-650-multimodal-screener-at-vision-expo-2023/2481461/Visionix announces a new multimodal device update with its second-generation VX 650. Launched in 2021, the VX 650 is an advanced anterior segment analyzer with retinal imaging. The enhanced wavefront-based aberrometer's "quick mode" and new capture flexibilities can decrease screeni
- Ophtec Celebrates 40 Year Anniversary with New Brand Identityhttps://modernod.com/news/ophtec-celebrates-40-year-anniversary-with-new-brand-identity/2481460/Ophtec is celebrating its 40th anniversary in 2023 and launching a new brand identity, "Modernized and fit for the future." Ophtec was founded in 1983 by the Dutch ophthalmologist Prof. Dr. Jan Worst, also known as the inventor of the world’s first Iris fi
- Sight Sciences Launches the Ergo-Series of the OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-launches-the-ergo-series-of-the-omni-surgical-system/2481457/Sight Sciences announced the US launch of the Ergo-Series of the OMNI Surgical System, a technology designed to facilitate surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma. The OMNI Sur